WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience MBF Stereo Investigator
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robertson, G. S.
Right arrow Articles by Robertson, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robertson, G. S.
Right arrow Articles by Robertson, H. A.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 9, 3326-3331, Copyright © 1989 by Society for Neuroscience

ARTICLE

Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms

GS Robertson and HA Robertson
Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

Parkinson's disease results from the death of the dopamine-containing neurons in the substantia nigra pars compacta (SNC). This is accompanied by a loss of dopamine in brain regions, such as the corpus striatum, which receives input from dopaminergic neurons in the substantia nigra (SN). Since the corpus striatum is the primary target for these dopaminergic neurons, it has long been thought that the corpus striatum is the principal region affected. It was, therefore, natural to assume that replenishing dopamine in the striatum might be an effective treatment for Parkinson's disease. In fact, the dopamine precursor L-dihydroxyphenylalanine (L-dopa), the current drug of choice for treatment of Parkinson's disease, is believed to exert its therapeutic effect by replenishing dopamine levels in the corpus striatum via enzymatic decarboxylation within the synaptic terminals of surviving nigrostriatal neurons (Hornykiewicz, 1974). However, dopamine is also synthesized, stored, and released from the dendrites of SNC neurons that arborize in the substantia nigra pars reticulata (SNR) (Cheramy et al., 1981). Using a classic animal model for Parkinson's disease (rats with a unilateral 6-hydroxydopamine lesion of the SN), we show that L-dopa is also converted to dopamine in significant amounts within the 6-OHDA-lesioned SN. Furthermore, in contrast to the situation in the striatum where dopamine levels are only elevated for a short time, dopamine levels in the SN remain elevated until the behavioral effects of L-dopa have subsided. This elevation of nigral dopamine levels produces rotation that can be blocked by injecting a selective D1 dopamine receptor antagonist (SCH 23390, 2 micrograms in 1 microliter) directly into the SN pars reticulata. Infusion of SCH 23390 into the ipsilateral striatum produced only a modest reduction in L- dopa-induced circling behavior. These results suggest that D1 dopamine receptors in the SN may be at least as important as D1 dopamine receptors in the striatum as a site for the effects of L-dopa. This may have important implications for the therapy of Parkinson's disease.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
T. Kawasaki, K. Ishihara, Y. Ago, A. Baba, and T. Matsuda
Edaravone (3-Methyl-1-phenyl-2-pyrazolin-5-one), a Radical Scavenger, Prevents 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Neurotoxicity in the Substantia Nigra but Not the Striatum
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 274 - 281.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Marti, C. Trapella, R. Viaro, and M. Morari
The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and L-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic Pathway
J. Neurosci., February 7, 2007; 27(6): 1297 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. E. Westin, H. S. Lindgren, J. Gardi, J. R. Nyengaard, P. Brundin, P. Mohapel, and M. A. Cenci
Endothelial Proliferation and Increased Blood-Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-L-Alanine-Induced Dyskinesia
J. Neurosci., September 13, 2006; 26(37): 9448 - 9461.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
O. Ibanez-Sandoval, A. Hernandez, B. Floran, E. Galarraga, D. Tapia, R. Valdiosera, D. Erlij, J. Aceves, and J. Bargas
Control of the Subthalamic Innervation of Substantia Nigra Pars Reticulata by D1 and D2 Dopamine Receptors
J Neurophysiol, March 1, 2006; 95(3): 1800 - 1811.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. D. Smith, S. J. Crocker, V. Jackson-Lewis, K. L. Jordan-Sciutto, S. Hayley, M. P. Mount, M. J. O'Hare, S. Callaghan, R. S. Slack, S. Przedborski, et al.
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease
PNAS, November 11, 2003; 100(23): 13650 - 13655.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. J. Crocker, P. D. Smith, V. Jackson-Lewis, W. R. Lamba, S. P. Hayley, E. Grimm, S. M. Callaghan, R. S. Slack, E. Melloni, S. Przedborski, et al.
Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease
J. Neurosci., May 15, 2003; 23(10): 4081 - 4091.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. S. Cobb and E. D. Abercrombie
Distinct Roles for Nigral GABA and Glutamate Receptors in the Regulation of Dendritic Dopamine Release under Normal Conditions and in Response to Systemic Haloperidol
J. Neurosci., February 15, 2002; 22(4): 1407 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
B. T. Chen and M. E. Rice
Novel Ca2+ Dependence and Time Course of Somatodendritic Dopamine Release: Substantia Nigra versus Striatum
J. Neurosci., October 1, 2001; 21(19): 7841 - 7847.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. H. Chartoff, B. T. Marck, A. M. Matsumoto, D. M. Dorsa, and R. D. Palmiter
Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation
PNAS, August 17, 2001; (2001) 181356498.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. F. Hoffman, C. R. Lupica, and G. A. Gerhardt
Dopamine Transporter Activity in the Substantia Nigra and Striatum Assessed by High-Speed Chronoamperometric Recordings in Brain Slices
J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 487 - 496.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Yokoyama and H. Okamura
Self-Injurious Behavior and Dopaminergic Neuron System in Neonatal 6-Hydroxydopamine-Lesioned Rat: 1. Dopaminergic Neurons and Receptors
J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1016 - 1030.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Okamura, T. Murakami, C. Yokoyama, T. Nakamura, and Y. Ibata
Self-Injurious Behavior and Dopaminergic Neuron System in Neonatal 6-Hydroxydopamine-Lesioned Rat: 2. Intracerebral Microinjection of Dopamine Agonists and Antagonists
J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1031 - 1037.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. H. Chartoff, B. T. Marck, A. M. Matsumoto, D. M. Dorsa, and R. D. Palmiter
Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation
PNAS, August 28, 2001; 98(18): 10451 - 10456.
[Abstract] [Full Text] [PDF]


-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-